Summarized by Masters of Longevity from PR Newswire.
Readers will open a short real-world analysis exploring what happened when adults stopped injectable GLP-1 therapies and started an oral semaglutide pill. The piece highlights patient experience, weight-change trends, and practical considerations from telehealth-collected data.
Key Takeaways
- Adults who switched from injectable GLP-1 therapies to oral semaglutide lost an average of 4.1% body weight after three months.
- The proportion of patients with obesity (BMI ≥30 kg/m²) decreased from 87.1% at baseline to 65.5% after three months.
- The OCTANE real-world study is observational and subject to self-reporting, selection bias, and limited generalizability.
